A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.
about
Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradationDeregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerRole of cell cycle regulators in lung carcinogenesisAlterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours.GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas.E3 ubiquitin ligases as cancer targets and biomarkers.Oncogenic aberrations of cullin-dependent ubiquitin ligases.Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes.SCF E3 ubiquitin ligases as anticancer targets.Tungsten-induced carcinogenesis in human bronchial epithelial cells.Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.Expression of Skp2 and p27(kip1) proteins in hypopharyngeal squamous cell carcinoma and its clinical significanceThe E3 ubiquitin ligase skp2 regulates neural differentiation independent from the cell cycle.Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.Ubiquitin-mediated control of oncogene and tumor suppressor gene products.Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2.Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.Role of E3 ubiquitin ligases in lung cancer.Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes.High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma.Human positive coactivator 4 is a potential novel therapeutic target in non-small cell lung cancer.Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells.Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry.BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line.Skp2 expression is associated with down-regulation of p27 protein and cell proliferation in salivary adenoid cystic carcinoma.The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells.Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference.Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma.Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition.Down-regulation of SKP2 induces apoptosis in lung-cancer cells.Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi.SKP2 Activation by Thyroid Hormone Receptor β2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells.Dysregulated expression of SKP2 and its role in hematological malignancies.
P2860
Q54605443-E0D995EF-46C0-485B-BD6D-5C44E7121BB9Q54608100-447711C5-376E-4313-9000-A980E2ADB2F4Q54608104-2E968BF8-FD94-4990-B90C-523369608324Q54608106-99FF7344-3122-4E78-8411-B5029300EB1AQ54608198-694572D0-5B89-4775-B272-83D90CD5C6A2Q54608221-5B214511-8F2B-4273-A4FE-9CC264F1996EQ54903190-F01F1479-5560-486C-9098-0B486EF1002FQ54903191-D958BDCB-9C5F-4FA4-8CBE-78535C686304Q54903192-E511E788-A846-43C8-8E85-108B1205C80BQ54903193-858806A3-807C-4D41-934E-3D6C7197A4A4Q54903194-A05A0345-96D5-4028-9E07-BE92F3B039A8Q54903195-8C35D72A-EAF6-406A-A992-9727DD335CABQ54903201-E533ADF2-1DA3-43FD-BFC2-AE03514AF3B8Q54903202-41F16C1A-86E4-4A56-A047-F37AA73C9D16Q54903203-3D1D6D75-0CC5-4437-90E2-F335FE10F519Q54903204-9A7FC93B-6605-41C4-B36F-12AD7256E4A9Q54903205-C0BEA4A4-EB2B-4D64-B149-7DC670CFB444Q54938461-4203D357-C1D2-4AF8-B847-43130F151DDFQ54951523-EBF61127-EEB0-4E3A-9F4F-D566E3D1AB27Q54951525-F93BD735-BFB2-49F3-B33E-E304F37C76D3Q54952168-4A8BC407-6385-45C6-BE55-7E4F05A1C369Q54952179-1075E214-D00C-41FD-BD90-D60FA0097869
P1343
Q24669893-F43714EF-6A2E-433F-A1CD-4433BEE0FB5FQ24803723-06D8EF46-1A65-4617-A35E-2144E4C90014Q28394676-8191D473-3221-432C-8C26-153D8E620891Q31021913-374F2441-F1A2-40D1-986A-EB2C191233B9Q33555212-BA50E7AB-A790-4768-82F1-5FBF47A2586DQ33697172-AE0F71ED-13C3-4D9A-BC4E-E96D51FBC56EQ34534399-2DA8F387-FA0C-4174-9AE7-3F1F806983E8Q35082710-E374ADF4-EBAE-41F4-ABE1-457142ED7D27Q35691547-D2DDDACB-180C-46F8-A559-088A61F21CBBQ35831837-E03D11E3-4946-4FDF-86EA-DC4C5D20B914Q35880315-4B224824-4DC4-47F3-807C-1AD2288B0D3FQ36083532-2ED39EC1-938F-4A5D-9AB0-F484CDCFFD7EQ36160685-6DB514FD-6D17-43F9-B094-7B6B70A76B8DQ36334291-D19EB444-D418-4F6C-8C96-58CE86B59291Q36463015-BE3E9634-9B28-42A0-A368-587E46071D76Q37080006-8E61F479-C65F-4DDA-8866-04C6528C3321Q37478622-923019D2-5CDC-4CDD-89C5-CE2735EC4049Q37491240-EF84B658-8841-4A60-A8C2-4F0E32AF8BE6Q37706977-64E6893B-E069-43B1-AE4D-F7FA0E285F1DQ37775627-0F20B120-7892-42A6-9803-FB08342E3ED7Q38128316-D5FA4D3E-FB9F-4EF6-BEA7-A4ECA8B3ECD9Q38780983-D4EAF5A5-E133-4A44-AB3B-ED23754F0D70Q38991023-0305F6D5-FAE6-47AB-A452-77019E16CDE1Q39291884-C2D7316E-AEF9-4405-B732-658EE624C9D0Q39666337-C89F1753-4231-4B90-9794-8C1622B452D5Q39752027-31E088A5-85E7-44A4-BFD1-3A8C9F604B01Q39832776-FC92253B-989A-4796-9038-F41E0A95E0B4Q39890176-27ABF010-0D2E-45A0-BF18-1303A7EC384AQ39923417-840ECBF3-C1DD-434A-A2C7-0C904DE790ABQ40141213-270B99A7-13A4-451D-8393-202275B770FFQ40146164-16F9CFCB-EAB7-4E34-901F-72A91FD2C354Q40460488-616E0B4D-D2C4-4B33-A65A-127BC84F7C26Q40512300-F7BC1399-93B7-40AB-BC80-D80FF430A9E5Q41593107-E17B216C-2BC4-474C-934C-7E3F9A625BBAQ42803466-2D5D766A-8C00-4146-B4F2-D47B1CFF2BA0Q42819481-38A7BEF1-A71B-4A11-88F4-040C37E21B04Q44490324-E95263FF-BDF8-498C-B521-1524057BEC45Q45885548-A7EB126C-F860-400A-AD6F-13FE606A7AB0Q47567989-5D0EDE6C-90AA-4F3A-A35C-094F5D318762Q47967824-DDF704C7-263A-4706-96D0-083609BF006B
P2860
A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A novel target gene, SKP2, wit ...... ed in small cell lung cancers.
@ast
A novel target gene, SKP2, wit ...... ed in small cell lung cancers.
@en
type
label
A novel target gene, SKP2, wit ...... ed in small cell lung cancers.
@ast
A novel target gene, SKP2, wit ...... ed in small cell lung cancers.
@en
prefLabel
A novel target gene, SKP2, wit ...... ed in small cell lung cancers.
@ast
A novel target gene, SKP2, wit ...... ed in small cell lung cancers.
@en
P2093
P2860
P4510
P1476
A novel target gene, SKP2, wit ...... ted in small cell lung cancers
@en
P2093
Fumiko Saito-Ohara
Johji Inazawa
Katsumi Koshikawa
Kohichiroh Yasui
Sana Yokoi
Setsuo Hirohashi
Takehiko Fujisawa
Takeo Terasaki
Toshihiko Iizasa
P2860
P304
P356
10.1016/S0002-9440(10)64172-7
P407
P577
2002-07-01T00:00:00Z